Clinical Characteristics and Overall Survival Prognostic Nomogram for Oligodendroglioma: A Surveillance, Epidemiology, and End Results Population-Based Analysis

被引:10
作者
Cao, Liang [1 ]
Rong, Ping [2 ]
Zhu, Guannan [1 ]
Xu, Aigang [1 ]
Chen, Si [3 ]
机构
[1] Nanjing Univ, Affiliated Taikang Xianlin Drum Tower Hosp, Med Sch, Dept Neurosurg, Nanjing, Peoples R China
[2] Nanjing Univ, Affiliated Taikang Xianlin Drum Tower Hosp, Dept Med Imaging, Affiliated Drum Tower Hosp,Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ, Affiliated Taikang Xianlin Drum Tower Hosp, Dept Med, Med Sch, Nanjing, Peoples R China
关键词
Nomogram; Oligodendroglioma;   Prognosis; SEER database; CENTRAL-NERVOUS-SYSTEM; CLASSIFICATION; PROCARBAZINE; VINCRISTINE; LOMUSTINE; MODELS; TRENDS; TUMORS;
D O I
10.1016/j.wneu.2021.04.122
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: Oligodendroglioma is a rare primary malignant brain tumor that has highly variable clinical outcomes. The aim of this study was to investigate demographics, outcomes, and prognostic factors of all oligodendroglioma cases from the Surveillance, Epidemiology, and End Results database to build a clinical prognosis model to predict survival time of patients with oligodendroglioma. METHODS: Cases diagnosed between 1975 and 2016 were selected from the Surveillance, Epidemiology, and End Results database. Age, sex, race, insurance, year of diagnosis, marital status, tumor location, tumor size, summary stage, surgery method, and use of radiotherapy and chemotherapy were evaluated with respect to overall survival by univariate and multivariate analysis. A nomogram predicting 5-and 10-year survival probability for oligodendroglioma was constructed and validated. RESULTS: After data cleaning, 4568 patients with oligodendroglioma were included. At the time of last follow-up, mean survival times among grade II and grade III oligodendrogliomas were 74 and 39 months, respectively. In multivariate analysis, radiotherapy, age, tumor site, summary stage, and surgery demonstrated independent associations with survival in both cohorts. Race and radiotherapy demonstrated independent associations with survival in grade II oligodendroglioma. Sex and chemotherapy demonstrated independent associations with survival in grade III oligodendroglioma. Independent factors in & nbsp;either cohort were selected to build a clinical nomogram. The C-index for the nomogram was 0.738 (95% confidence interval 0.718-0.757). The calibration curves of 5-and 10-year survival rates showed good agreement between the nomogram predictions and actual observations. CONCLUSIONS: This study was the first to develop a nomogram for predicting overall survival of patients with oligodendroglioma to help clinicians predict patient prognosis accurately and conduct further treatment.
引用
收藏
页码:E810 / E820
页数:11
相关论文
共 31 条
[1]   Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis [J].
Alattar, Ali A. ;
Brandel, Michael G. ;
Hirshman, Brian R. ;
Dong, Xuezhi ;
Carroll, Kate T. ;
Ali, Mir Amaan ;
Carter, Bob S. ;
Chen, Clark C. .
JOURNAL OF NEUROSURGERY, 2018, 128 (04) :1076-1083
[2]   Discrimination and Calibration of Clinical Prediction Models Users' Guides to the Medical Literature [J].
Alba, Ana Carolina ;
Agoritsas, Thomas ;
Walsh, Michael ;
Hanna, Steven ;
Iorio, Alfonso ;
Devereaux, P. J. ;
McGinn, Thomas ;
Guyatt, Gordon .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (14) :1377-1384
[3]   Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma [J].
Bell, Erica H. ;
Zhang, Peixin ;
Shaw, Edward G. ;
Buckner, Jan C. ;
Barger, Geoffrey R. ;
Bullard, Dennis E. ;
Mehta, Minesh P. ;
Gilbert, Mark R. ;
Brown, Paul D. ;
Stelzer, Keith J. ;
McElroy, Joseph P. ;
Fleming, Jessica I. ;
Timmers, Cynthia D. ;
Becker, Aline P. ;
Salavaggione, Andrea L. ;
Liu, Ziyan ;
Aldape, Kenneth ;
Brachman, David G. ;
Gertler, Stanley Z. ;
Murtha, Albert D. ;
Schultz, Christopher J. ;
Johnson, David ;
Laack, Nadia N. ;
Hunter, Grant K. ;
Crocker, Ian R. ;
Won, Minhee ;
Chakravarti, Arnab .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29) :3407-3417
[4]  
Bent M, 2017, J CLIN ONCOL, V35
[5]   Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis [J].
Brandel, Michael G. ;
Alattar, Ali A. ;
Hirshman, Brian R. ;
Dong, Xuezhi ;
Carroll, Kate T. ;
Ali, Mir Amaan ;
Carter, Bob S. ;
Chen, Clark C. .
JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (01) :173-181
[6]   Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402 [J].
Cairncross, Gregory ;
Wang, Meihua ;
Shaw, Edward ;
Jenkins, Robert ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperriere, Normand ;
Curran, Walter ;
Mehta, Minesh .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :337-343
[7]   Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH [J].
Cairncross, J. Gregory ;
Wang, Meihua ;
Jenkins, Robert B. ;
Shaw, Edward G. ;
Giannini, Caterina ;
Brachman, David G. ;
Buckner, Jan C. ;
Fink, Karen L. ;
Souhami, Luis ;
Laperriere, Normand J. ;
Huse, Jason T. ;
Mehta, Minesh P. ;
Curran, Walter J., Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :783-+
[8]   Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System Clinical article [J].
Chang, Edward F. ;
Clark, Aaron ;
Jensen, Randy L. ;
Bernstein, Mark ;
Guha, Abhijit ;
Carrabba, Giorgio ;
Mukhopadhyay, Debabrata ;
Kim, Won ;
Liau, Linda M. ;
Chang, Susan M. ;
Smith, Justin S. ;
Berger, Mitchel S. ;
McDermott, Michael W. .
JOURNAL OF NEUROSURGERY, 2009, 111 (02) :203-210
[9]   Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial [J].
Dubbink, Hendrikus J. ;
Atmodimedjo, Peggy N. ;
Kros, Johan M. ;
French, Pim J. ;
Sanson, Marc ;
Idbaih, Ahmed ;
Wesseling, Pieter ;
Enting, Roelien ;
Spliet, Wim ;
Tijssen, Cees ;
Dinjens, Winand N. M. ;
Gorlia, Thierry ;
van den Bent, Martin J. .
NEURO-ONCOLOGY, 2016, 18 (03) :388-400
[10]   Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors [J].
Eckel-Passow, Jeanette E. ;
Lachance, Daniel H. ;
Molinaro, Annette M. ;
Walsh, Kyle M. ;
Decker, Paul A. ;
Sicotte, Hugues ;
Pekmezci, Melike ;
Rice, Terri ;
Kosel, Matt L. ;
Smirnov, Ivan V. ;
Sarkar, Gobinda ;
Caron, Alissa A. ;
Kollmeyer, Thomas M. ;
Praska, Corinne E. ;
Chada, Anisha R. ;
Halder, Chandralekha ;
Hansen, Helen M. ;
Mccoy, Lucie S. ;
Bracci, Paige M. ;
Marshall, Roxanne ;
Zheng, Shichun ;
Reis, Gerald F. ;
Pico, Alexander R. ;
O'Neill, Brian P. ;
Buckner, Jan C. ;
Giannini, Caterina ;
Huse, Jason T. ;
Perry, Arie ;
Tihan, Tarik ;
Berger, Mitchell S. ;
Chang, Susan M. ;
Prados, Michael D. ;
Wiemels, Joseph ;
Wiencke, John K. ;
Wrensch, Margaret R. ;
Jenkins, Robert B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2499-2508